Saturday, March 05, 2016 10:26:29 AM
The grant money isn't set aside for the trial participants specifically. Instead it is set aside to reimburse NWBO for the cost of manufacturing (getting manufacturing ready and the cost of vaccine production for the trial participants which may not include the HE program participant's vaccine production. But the manufacturing site will be used for both the trial and HE patients, but I would agree with you that most likely the German HE program is separate from the German Grant and that program has its major issues of ever being realized in terms of getting reimbursements ever negotiated successfully (IMO based on reading the ridiculous hurdles placed for those negotiations). Also, the SEC docs show that NWBO appears to be recognizing revenue way BEFORE they even treat their first German patient and even before they start "receiving" reimbursement from the German Grant- all kosher with accrual accting according to GAAP. There are other interesting stuff related to those reimbursements but that would be too much for this post.
"Bethesda, Maryland, May 1, 2012 – Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO) (NW Bio) today announced that, working together with the Fraunhofer Institute (IZI), it has received approval of a major grant from the Sächsische Aufbau Bank (SAB or Saxony Development Bank) in Germany. The grant will reimburse fifty percent (50%) of the costs for manufacturing in Germany and for NW Bio’s clinical trial with DCVax®-L for brain cancer at up to 30 clinical sites in Germany. The amount of the grant will be €4.15 million (~$5.5 million)."
Concerning CXCR4, still unproven how effective and useful it will be in a clinical setting, and IMO will only show potential in a combo trial with some other therapeutic therapy like a cancer vaccine or checkpoint inhibitor. As a mono-therapy, again IMO it would be too costly to use since it's MOA doesn't necessarily "cure" cancer but seems useful for maintenance therapy (I guess it depends on the cost of manufacturing for the receptor peptide inhibitors and how effective it is for maintenance therapy measured by durable responses for SD or prolonged PFS/OS. As I stated before MANY times, it will be costly to look at those endpoints, and for most cancer therapies, the fastest route is to look for durable ORR results which is why I'm so negative on Direct and am not surprised that it is taking so long to design the second part of that pI/II Direct trial. JMHO and best wishes to you as well.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM